Developer docs
API playgroundTry for free, no card

Search company profiles

BVCF

Full company profile

uuid000ajfd

Namestring
BVCF
Legal namestring
BVCF Management Ltd.
Websiteurl
bvcf.com
Company typeenum
Private
Founded yearint
2005
Descriptiontext

BVCF (BioVeda China Fund / 百奥维达) is a Shanghai-headquartered private equity and venture capital firm founded in 2005 by Dr. Zhi Yang as China's first USD-denominated fund dedicated to life sciences and healthcare. The firm invests growth-stage capital into innovative Chinese and US healthcare companies across innovative biologics, in-vitro diagnostics and molecular diagnostics, high-value medical devices and consumables, medical big data, online medical consultation, and e-commerce pharmacy. BVCF has raised five funds, manages approximately US$722 million in assets, and has syndicated over US$1 billion in co-investment opportunities to its limited partners. Its portfolio spans roughly 50 companies and has produced multiple liquidity events including Biocytogen's dual H+A listing (HKEx 02315.HK in September 2022 and STAR Market 688796.SH in December 2025), Oculis' Nasdaq listing (March 2023), DiaCarta's announced NYSE SPAC merger (2022), and CARsgen's HKEx listing.

BVCF generates revenue through standard private equity economics: management fees (typically 1.5–2% of committed capital) and carried interest (typically 20% of profits above a hurdle rate). The firm distributes its fund offerings through direct institutional relationships rather than retail channels, and its limited-partner base includes sovereign wealth funds (Temasek, GIC), multilateral institutions (World Bank/IFC), asset managers (BlackRock, UBS, Neuberger Berman, Morgan Stanley), strategic corporates (Novartis, Johnson & Johnson, Mitsubishi, Lilly Asia Ventures), and healthcare operators (Mayo Clinic). BVCF has a small core team (~14 professionals) with a hybrid scientific-operational profile — Harvard PhDs, former faculty from Rockefeller University and Harvard Medical School, ex-J.P. Morgan healthcare bankers, and senior M&A operators from Rothschild and HSBC — and operates from offices in Shanghai (headquarters, Suite 2604, No. 763 Mengzi Road, Huangpu District) and Hong Kong (BVCF Management (Hong Kong) Limited, Hong Kong Science Park).

Short descriptiontext

BVCF (BioVeda China Fund) is a Shanghai-headquartered private equity firm founded in 2005 that manages ~US$722M across five funds dedicated to growth-stage life sciences and healthcare companies in China and the US, backed by sovereign wealth, multilateral, and strategic corporate LPs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
private equity funds, life sciences investment, healthcare venture capital, growth-stage equity, China healthcare investing
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Healthcare Private Equity Fund Management
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeLicensing Royalties
Description

BVCF generates revenue through management fees (typically 1.5-2% of committed capital) and carried interest (typically 20% of profits above the hurdle rate) from managing its private equity funds. The fund has raised multiple funds over its history.

bvcf.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BVCF (BioVeda China Fund) is a private equity fund management firm founded in 2005 that raises capital from global institutional and strategic investors and invests it into growth-stage life sciences and healthcare companies in China and the United States. Across five funds and US$722 million under management, BVCF deploys growth equity, provides strategic and operational support, and pursues exits through IPOs and trade sales in healthcare services, innovative biologics, in-vitro diagnostics, medical devices, medical big data, and mobile medicine.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Invested in nearly 50 companies over 16 years
+2 more records
Product overview1 text field

BVCF (BioVeda China Fund) is a private equity investment firm, not a product or technology company. BVCF Management Ltd. is a healthcare investment company that launches and manages funds investing in global growth-stage healthcare companies with a China focus. The company has raised five funds and has approximately US$722 million under management. BVCF's investment strategy focuses on creating and developing innovative global Chinese Life Sciences companies, covering areas including innovative biologics, in-vitro diagnostics (molecular diagnostics), high-value medical devices and consumables, medical big data, online medical consultation, and e-commerce pharmacy. The firm operates from headquarters in Shanghai, China with offices in Beijing and Hong Kong SAR.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move11 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment28 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BVCF

Healthcare Private Equity Fund Managementbvcf.com

BVCF (BioVeda China Fund) is a Shanghai-headquartered private equity firm founded in 2005 that manages ~US$722M across five funds dedicated to growth-stage life sciences and healthcare companies in China and the US, backed by sovereign wealth, multilateral, and strategic corporate LPs.

What BVCF does

BVCF (BioVeda China Fund / 百奥维达) is a Shanghai-headquartered private equity and venture capital firm founded in 2005 by Dr. Zhi Yang as China's first USD-denominated fund dedicated to life sciences and healthcare. The firm invests growth-stage capital into innovative Chinese and US healthcare companies across innovative biologics, in-vitro diagnostics and molecular diagnostics, high-value medical devices and consumables, medical big data, online medical consultation, and e-commerce pharmacy. BVCF has raised five funds, manages approximately US$722 million in assets, and has syndicated over US$1 billion in co-investment opportunities to its limited partners. Its portfolio spans roughly 50 companies and has produced multiple liquidity events including Biocytogen's dual H+A listing (HKEx 02315.HK in September 2022 and STAR Market 688796.SH in December 2025), Oculis' Nasdaq listing (March 2023), DiaCarta's announced NYSE SPAC merger (2022), and CARsgen's HKEx listing.

BVCF generates revenue through standard private equity economics: management fees (typically 1.5–2% of committed capital) and carried interest (typically 20% of profits above a hurdle rate). The firm distributes its fund offerings through direct institutional relationships rather than retail channels, and its limited-partner base includes sovereign wealth funds (Temasek, GIC), multilateral institutions (World Bank/IFC), asset managers (BlackRock, UBS, Neuberger Berman, Morgan Stanley), strategic corporates (Novartis, Johnson & Johnson, Mitsubishi, Lilly Asia Ventures), and healthcare operators (Mayo Clinic). BVCF has a small core team (~14 professionals) with a hybrid scientific-operational profile — Harvard PhDs, former faculty from Rockefeller University and Harvard Medical School, ex-J.P. Morgan healthcare bankers, and senior M&A operators from Rothschild and HSBC — and operates from offices in Shanghai (headquarters, Suite 2604, No. 763 Mengzi Road, Huangpu District) and Hong Kong (BVCF Management (Hong Kong) Limited, Hong Kong Science Park).

BVCF firmographics

Firmographics
Name
BVCF
Legal name
BVCF Management Ltd.
Website
https://bvcf.com
Company type
Private
Founded year
2005
Operating status
Operating
Headcount range
11–50 employees
Short description
BVCF (BioVeda China Fund) is a Shanghai-headquartered private equity firm founded in 2005 that manages ~US$722M across five funds dedicated to growth-stage life sciences and healthcare companies in China and the US, backed by sovereign wealth, multilateral, and strategic corporate LPs.
Ownership category
akta.pro rank

Where BVCF is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

BVCF business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Fund Management: BVCF generates revenue through management fees (typically 1.5-2% of committed capital) and carried interest (typically 20% of profits above the hurdle rate) from managing its private equity funds. The fund has raised multiple funds over its history.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

BVCF product offering

Product offering

Core offering

BVCF (BioVeda China Fund) is a private equity fund management firm founded in 2005 that raises capital from global institutional and strategic investors and invests it into growth-stage life sciences and healthcare companies in China and the United States. Across five funds and US$722 million under management, BVCF deploys growth equity, provides strategic and operational support, and pursues exits through IPOs and trade sales in healthcare services, innovative biologics, in-vitro diagnostics, medical devices, medical big data, and mobile medicine.

Product overview

BVCF (BioVeda China Fund) is a private equity investment firm, not a product or technology company. BVCF Management Ltd. is a healthcare investment company that launches and manages funds investing in global growth-stage healthcare companies with a China focus. The company has raised five funds and has approximately US$722 million under management. BVCF's investment strategy focuses on creating and developing innovative global Chinese Life Sciences companies, covering areas including innovative biologics, in-vitro diagnostics (molecular diagnostics), high-value medical devices and consumables, medical big data, online medical consultation, and e-commerce pharmacy. The firm operates from headquarters in Shanghai, China with offices in Beijing and Hong Kong SAR.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Invested in nearly 50 companies over 16 years
  • +2 more outcomes

Companies that use BVCF

Customer profile

Segments2 records

Ideal customer profiles2 records

BVCF technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BVCF partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves11 records

Expansion highlights5 records

BVCF competitors and assessment

Company assessment

Market position

Weaknesses4 records

Competitive moat4 records

Customer concentration

BVCF financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BVCF leadership team

Management profile

Number of profiles

Profiles14 records

BVCF funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BVCF M&A and investment

M&A and investment

M&A

Investments28 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BVCF

What does BVCF do?

BVCF (BioVeda China Fund) is a private equity fund management firm founded in 2005 that raises capital from global institutional and strategic investors and invests it into growth-stage life sciences and healthcare companies in China and the United States. Across five funds and US$722 million under management, BVCF deploys growth equity, provides strategic and operational support, and pursues exits through IPOs and trade sales in healthcare services, innovative biologics, in-vitro diagnostics, medical devices, medical big data, and mobile medicine.

Is BVCF a public or private company?

BVCF is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was BVCF founded?

BVCF was founded in 2005. It employs 11 to 50 people.

Where is BVCF based?

BVCF is headquartered in Shanghai, China, in the Asia region.

How does BVCF make money?

One revenue line is on record: fund Management.

Does BVCF have an API?

No public API is recorded for BVCF.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsDrug Farm Raises $55M in First Close of Series D FundingDrug Farm raised $55M in its first Series D financing round, led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership Enterprise. The company will use the funds to advance its clinical and preclinical pipeline, accelerate global clinical development, and expand R&D capabilities.MorningstarDrug Farm Completes First Closing of $55 Million Series D Financing to Advance Clinical and Preclinical Development PipelineDrug Farm closed its first $55 million Series D financing, co-led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund. The funds will advance clinical and preclinical development, including DF-003's Phase 3 trial for ROSAH syndrome and DF-006 for hepatitis B.InnovationMapHouston biotech company raises $15M round led by Chinese health care investorHouston-based biotech startup Cellenkos closed a $15 million Series A funding round led by Shanghai-based BVCF Management. The capital will be used to advance research and development of its T regulatory cell therapies for autoimmune and inflammatory disorders, including launching a phase 1b trial for myelofibrosis treatment. The company was founded by Dr. Simrit Parmar and Golden Meditech Holdings Limited.PR NewswireCellenkos® Inc. Secures $15 Million Series A Financing to Accelerate the Development of Transformation Cell-Based TherapiesCellenkos Inc. has closed a $15 million Series A financing round led by BVCF Management Ltd to accelerate the development of its transformation cell-based therapies for autoimmune and inflammatory disorders. The company intends to use these proceeds to advance its Treg cell therapy platform, which includes lead products CK0802 and CK0804.NorthstackOculis raises $57m Series C led by BVCF Management and Hyfinity InvestmentsOculis Pharma, an Iceland-founded biopharmaceutical company based in Lausanne, Switzerland, closed an oversubscribed $57 million Series C round co-led by new investors BVCF Management and Hyfinity Investments, with VI Partners and Wille AG joining existing backers. The company said proceeds will accelerate development of novel topical therapies for ophthalmic diseases targeting the retina and anterior segment. Two new board members will join while co-founder Dr. Þorsteinn Loftsson steps down.FinSMEsOculis Closes US$57M Series C FinancingOculis S.A., a Lausanne-based biopharmaceutical company, closed a US$57 million Series C financing round co-led by BVCF Management and Hyfinity Investments. The proceeds will advance the clinical development of its ophthalmic portfolio, specifically moving OCS-01 into Phase 3 trials for Diabetic Macular Edema and advancing OCS-02 into Phase 2b trials for Dry Eye Disease. In conjunction with the financing, new investors joined the board while two existing directors stepped down.FinSMEsMicuRx Closes ¥100M FundingMicuRx Pharmaceuticals closed a ¥100M financing round led by Delian Capital and BVCF. The funds will support the Phase 3 program for oral antibiotic contezolid and the projected Chinese NDA filing. The company has raised $107M in total venture capital.PR NewswireMicuRx Announces Closing of ¥100 Million FundingMicuRx Pharmaceuticals announced closing of ¥100 million private financing led by Chinese affiliates of existing investors Delian Capital and BVCF. The funds will support completion of the ongoing Phase 3 program for oral antibiotic contezolid (MRX-I) and the projected Chinese NDA filing. The company also reported successful completion of Phase 1 studies for contezolid acefosamil (MRX-4), showing the drug was safe and well tolerated at all doses tested with no safety signals detected.FinSMEsMicuRx Pharmaceuticals Raises $25M in Series B FinancingMicuRx Pharmaceuticals raised $25M in Series B financing led by BVCF, with participation from Morningside Group and Devon Park Bioventures. The company will use the capital to fund U.S. development of MRX-I, an oral oxazolidinone antibiotic targeting multi-drug resistant Gram-positive bacteria. To date, it has raised $37M in funding.VC News DailyMicuRx Completes $25M Series BMicuRx Pharmaceuticals, a privately-held biopharmaceutical company based in Hayward, California developing next-generation antibiotics, announced it raised $25 million in Series B financing. The round was led by BVCF with participation from existing investors Morningside Group and Devon Park Bioventures, and proceeds will fund U.S. development of MRX-I, a novel oral antibiotic targeting multi-drug resistant Gram-positive bacteria including MRSA and VRE. BVCF partners Weixin Xu and Davis Yang will join MicuRx's board of directors as the company prepares to initiate Phase 2 clinical trials in both China and the United States.